Clinical Trial Update: AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid [Phase 3]

View source ↗

Summary

This update covers the Phase 3 AHEAD 3-45 study evaluating lecanemab for preclinical and early preclinical Alzheimer's disease; the trial is currently active an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Lecanemab (Leqembi) (lecanemab)

Snippet

Sponsor: Eisai Inc. | Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING